PE20171257A1 - Analogos de urea unidos sustituidos como moduladores de sirtuina - Google Patents

Analogos de urea unidos sustituidos como moduladores de sirtuina

Info

Publication number
PE20171257A1
PE20171257A1 PE2017000883A PE2017000883A PE20171257A1 PE 20171257 A1 PE20171257 A1 PE 20171257A1 PE 2017000883 A PE2017000883 A PE 2017000883A PE 2017000883 A PE2017000883 A PE 2017000883A PE 20171257 A1 PE20171257 A1 PE 20171257A1
Authority
PE
Peru
Prior art keywords
united
sirtuin modulators
urea analogs
sirtuin
refers
Prior art date
Application number
PE2017000883A
Other languages
English (en)
Inventor
James Lamond Ellis
Karen Anderson Evans
Ryan Michael Fox
William Henry Miller
Mark Andrew Seefeld
Original Assignee
Glaxosmithkline Intellectual Property (No 2) Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Intellectual Property (No 2) Ltd filed Critical Glaxosmithkline Intellectual Property (No 2) Ltd
Publication of PE20171257A1 publication Critical patent/PE20171257A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se refiere a un analogo de urea unido sustituido de formula (I), en donde R1 es -C(O)Ra o -C(O)-NRbRc; R2 es H, halogeno, entre otros; R3 es H, hidroxi, entre otros; R5 y R6 son H, -alquilo C1-C6 lineal o ramificado, entre otros Ra, Rb, Rc son H, -alquilo C1-C6, entre otros. Es un compuesto seleccionado: (9S)-8-N-(piridin-2-il)-5-N-(2,2,2-trifluoroetil))-1,6,8-triazatriciclo[7.2.1.02,7]dodeca-2(7),3,5-trieno-5,8-dicarboxamida; entre otros. Tambien se refiere a una composicion farmaceutica que lo comprende. Dicho analogo es un modulador de la sirtuina siendo util en el tratamiento de trastornos relacionados con el envejecimiento, tension, diabetes, entre otros
PE2017000883A 2014-11-19 2015-11-19 Analogos de urea unidos sustituidos como moduladores de sirtuina PE20171257A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462081916P 2014-11-19 2014-11-19

Publications (1)

Publication Number Publication Date
PE20171257A1 true PE20171257A1 (es) 2017-08-28

Family

ID=54705247

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2017000883A PE20171257A1 (es) 2014-11-19 2015-11-19 Analogos de urea unidos sustituidos como moduladores de sirtuina

Country Status (21)

Country Link
US (4) US10072011B2 (es)
EP (4) EP3220918A1 (es)
JP (4) JP6806679B2 (es)
KR (4) KR20170083133A (es)
CN (4) CN107207521A (es)
AU (4) AU2015348942B2 (es)
BR (4) BR112017010602A2 (es)
CA (4) CA2968027A1 (es)
CL (1) CL2017001275A1 (es)
CO (1) CO2017004994A2 (es)
CR (1) CR20170209A (es)
DO (1) DOP2017000123A (es)
EA (1) EA201791074A1 (es)
ES (1) ES2823748T3 (es)
IL (1) IL252252A0 (es)
MX (1) MX2017006658A (es)
PE (1) PE20171257A1 (es)
PH (1) PH12017500913A1 (es)
RU (3) RU2017120857A (es)
SG (1) SG11201703824QA (es)
WO (4) WO2016079712A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016086088A2 (en) * 2014-11-25 2016-06-02 Northwestern University Wound healing through sirt1 overexpression
CN108329388A (zh) * 2018-01-18 2018-07-27 天津市湖滨盘古基因科学发展有限公司 一种人的沉默配型信息调节蛋白突变蛋白及其应用
CN108395436B (zh) * 2018-05-14 2021-01-12 鹤壁市人民医院 一种咪唑并吡嗪医药中间体的制备方法
CN108707150B (zh) * 2018-05-14 2021-04-16 江苏惠利生物科技有限公司 一种咪唑并吡嗪医药中间体的制备方法
CN110478339A (zh) * 2019-08-12 2019-11-22 昆明理工大学 紫铆因在制备靶向恢复突变p53构象药物中的应用
KR20220056223A (ko) * 2019-09-02 2022-05-04 메르크 파텐트 게엠베하 유기 전계발광 디바이스용 재료
CN114890955A (zh) * 2022-06-23 2022-08-12 江西瑞威尔生物科技有限公司 一种n取代吗啉类有机化合物的制备工艺

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
WO2006094210A2 (en) * 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. Tetrahydroquinoxalinone sirtuin modulators
UA108596C2 (xx) 2007-11-09 2015-05-25 Інгібітори пептиддеформілази
KR20120092141A (ko) * 2009-10-29 2012-08-20 서트리스 파마슈티컬즈, 인코포레이티드 시르투인 조절제로서의 비시클릭 피리딘 및 유사체
AU2012352442A1 (en) * 2011-12-12 2014-07-03 Smb Innovation Aps Novel heterocyclic compounds useful in sirtuin binding and modulation
EP2997029B1 (en) * 2013-05-13 2019-01-09 GlaxoSmithKline LLC Substituted bridged urea analogs as sirtuin modulators

Also Published As

Publication number Publication date
EP3221317A1 (en) 2017-09-27
CA2968027A1 (en) 2016-05-26
BR112017010599A2 (pt) 2017-12-26
JP2017534664A (ja) 2017-11-24
EP3221317B1 (en) 2020-07-22
BR112017010602A2 (pt) 2017-12-26
KR20170087907A (ko) 2017-07-31
EP3221316A1 (en) 2017-09-27
CA2968029A1 (en) 2016-05-26
US10072011B2 (en) 2018-09-11
CN107108627A (zh) 2017-08-29
CN107207520A (zh) 2017-09-26
US20180319810A1 (en) 2018-11-08
KR20170083133A (ko) 2017-07-17
RU2017120857A (ru) 2018-12-19
MX2017006658A (es) 2018-01-15
CR20170209A (es) 2017-07-17
CA2968030A1 (en) 2016-05-26
WO2016079712A1 (en) 2016-05-26
JP2017534663A (ja) 2017-11-24
AU2015348944A1 (en) 2017-06-01
BR112017010601A2 (pt) 2017-12-26
EA201791074A1 (ru) 2017-10-31
CN107207521A (zh) 2017-09-26
CN107207509A (zh) 2017-09-26
CO2017004994A2 (es) 2017-09-20
AU2015348942B2 (en) 2018-07-05
CA2968032A1 (en) 2016-05-26
AU2015348942A1 (en) 2017-06-01
JP2017534662A (ja) 2017-11-24
EP3221322A1 (en) 2017-09-27
JP6806679B2 (ja) 2021-01-06
KR20170083135A (ko) 2017-07-17
US20190048016A1 (en) 2019-02-14
US20170362234A1 (en) 2017-12-21
KR20170083134A (ko) 2017-07-17
WO2016079711A1 (en) 2016-05-26
CL2017001275A1 (es) 2017-12-15
IL252252A0 (en) 2017-07-31
ES2823748T3 (es) 2021-05-10
DOP2017000123A (es) 2017-08-15
RU2017120858A (ru) 2018-12-19
AU2015348943A1 (en) 2017-06-01
CN107207509B (zh) 2020-04-21
RU2017120855A (ru) 2018-12-19
WO2016079709A1 (en) 2016-05-26
WO2016079710A1 (en) 2016-05-26
EP3220918A1 (en) 2017-09-27
BR112017010595A2 (pt) 2018-01-02
PH12017500913A1 (en) 2017-12-04
AU2015348941A1 (en) 2017-06-01
US20170355705A1 (en) 2017-12-14
SG11201703824QA (en) 2017-06-29
JP2017534665A (ja) 2017-11-24

Similar Documents

Publication Publication Date Title
PE20171257A1 (es) Analogos de urea unidos sustituidos como moduladores de sirtuina
PE20180024A1 (es) Triazolopirazinonas como inhibidores de pde1
DOP2016000339A (es) Compuestos de heteroarilo útiles como inhibidores de enzima activadora de sumo
DOP2016000144A (es) Moduladores de tetrahidropiridopirazinas de gpr6
PE20180462A1 (es) Moduladores cot y metodos de uso de los mismos
CR20170573A (es) Lactamas bicíclicas y métodos de uso de las mismas
CU20170073A7 (es) Compuestos de indazol sustituidos y compuestos intermediarios para la preparación de los mismos
SV2016005257A (es) Benzimidazol-2-aminas como inhibidores de midh1
AR099994A1 (es) Compuesto de ciclopropanamina y sus usos
DOP2015000270A (es) Potenciador de inhibidores del homólogo de zeste
CO7240375A2 (es) Compuestos tricíclicos sustituidos como inhibidores del fgfr
PE20170925A1 (es) Composiciones y metodos para el tratamiento de trastornos del snc
CO2018005315A2 (es) Moduladores de la interacción de sestrina-gator2 y sus usos
PE20142098A1 (es) Compuestos terapeuticamente activos y sus metodos de uso
UY36224A (es) Compuestos tricíclicos de imidazo-pirimidinona
CL2009000650A1 (es) Compuestos derivados de amino-pirazina, inhibidores de cinasa-pi 3; composicion farmaceutica; y uso para el tratamiento de condiciones inflamatorias o alérgicas, tales como enfermedades respiratorias, artritis reumatoide, colitis ulcerativa, entre otras
CL2018002089A1 (es) Maleato de agonista de tlr7, sus formas cristalinas c, d y e, sus procesos de preparación y su uso
DOP2013000130A (es) Compuestos de pirimidinona para uso en el tratamiento de las enfermedades o condiciones mediada por lp - pla2
AR088622A1 (es) 18-METIL-6,7-METILEN-3-OXO-17-PREGN-4-EN-21,17b-CARBOLACTONA, PREPARADOS FARMACEUTICOS QUE CONTIENEN LOS COMPUESTOS MENCIONADOS Y SU USO EN LA TERAPIA DE LA ENDOMETRIOSIS
PE20150623A1 (es) Moduladores de la ruta del complemento y usos de los mismos
CR20150171A (es) Benzamidas
PE20142376A1 (es) Fluormetil-5,6-dihidro-4h-[1,3]oxazinas
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
EA201591815A1 (ru) Бицикло [2.2.2] кислоты - модуляторы gpr120
UY33655A (es) Co-cristales y sales de inhibidores de ccr30

Legal Events

Date Code Title Description
FD Application declared void or lapsed